All-star team of synthetic biologists raise $53 million for cancer therapy startup Senti

 A who’s-who from the world of synthetic biological research have come together to launch Senti Biosciences with $53 million in funding from a slew of venture capital investors. Led by Tim Lu, a longtime researcher at the Massachusetts Institute of Technology and one of the founding fathers of synthetic biology, Senti’s aim is nothing less than developing therapies that are tailored… Read More

Responses are currently closed, but you can trackback from your own site.

Comments are closed.